Sun Pharma Evaluates $10 Billion Acquisition of US-Based Organon, Calls Reports Speculative

Sun Pharmaceutical Industries Ltd is reportedly evaluating a potential acquisition of US-based Organon, a women's health and biosimilars-focused company, in a deal valued around $10 billion including debt. Sun Pharma has submitted a non-binding all-cash offer and secured bridge financing from global banks, marking its largest overseas bid if completed. Organon, spun off from Merck in 2021 with significant debt, has been divesting assets to reduce leverage. Sun Pharma has described media reports on the deal as speculative and has not confirmed any material event requiring disclosure.